255 related articles for article (PubMed ID: 25145430)
1. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
Abraham I; Han L; Sun D; MacDonald K; Aapro M
Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
[TBL] [Abstract][Full Text] [Related]
2. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
3. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
4. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
Tunceli O; Bailey RA; Stephenson JJ; Singer J
J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
[TBL] [Abstract][Full Text] [Related]
5. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.
Kerkhofs L; Boschetti G; Lugini A; Stanculeanu DL; Palomo AG
Future Oncol; 2012 Jun; 8(6):751-6. PubMed ID: 22443466
[TBL] [Abstract][Full Text] [Related]
6. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of biosimilar epoetins in nephrology in the United States.
Fishbane S; Shah HH
Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
[TBL] [Abstract][Full Text] [Related]
9. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.
Hörbrand F; Rottenkolber D; Fischaleck J; Hasford J
Gesundheitswesen; 2014 Nov; 76(11):e79-84. PubMed ID: 24493578
[TBL] [Abstract][Full Text] [Related]
11. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
12. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
Yang MC
Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
[No Abstract] [Full Text] [Related]
13. The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.
Polsky D; Eremina D; Hess G; Hill J; Hulnick S; Roumm A; Whyte JL; Kallich J
Pharmacoeconomics; 2009; 27(9):755-65. PubMed ID: 19757869
[TBL] [Abstract][Full Text] [Related]
14. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
Berger A; Edelsberg J; Kallich J; Oster G
Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
[TBL] [Abstract][Full Text] [Related]
15. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis.
Ortega A; Dranitsaris G; Puodziunas AL
Cancer; 1998 Dec; 83(12):2588-96. PubMed ID: 9874467
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar Epoetin Zeta in Oncology and Haematology: Development and Experience following 6 Years of Use.
Michallet M; Losem C
Acta Haematol; 2016; 135(1):44-52. PubMed ID: 26426164
[TBL] [Abstract][Full Text] [Related]
17. Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy.
Berger A; Lord C; Corey-Lisle PK; Williams GR; Oster G
Clin Ther; 2012 Jun; 34(6):1350-63. PubMed ID: 22591754
[TBL] [Abstract][Full Text] [Related]
18. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
Noxon V; Knopf KB; Norris LB; Chen B; Yang YT; Qureshi ZP; Hrushesky W; Lebby AA; Schooley B; Hikmet N; Dickson M; Thamer M; Cotter D; Yarnold PR; Bennett CL
J Oncol Pract; 2017 Jun; 13(6):e562-e573. PubMed ID: 28504901
[TBL] [Abstract][Full Text] [Related]
19. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
Szucs TD; Blank PR; Schwenkglenks M; Aapro M
Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
[TBL] [Abstract][Full Text] [Related]
20. Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece.
Papachristos A; Kani C; Litsa P; Valsami G; Souliotis K; Saridi M; Markantonis S
Consult Pharm; 2016 May; 31(5):271-81. PubMed ID: 27178657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]